TABLE 5.
Inhibitory activity of CBAs to pradimicin A-exposed HIV-1(IIIB) isolates in CEM cell culturesa
| Compound | EC50 (μg/ml) for indicated isolate:
|
||||||
|---|---|---|---|---|---|---|---|
| HIV-1(IIIB) | PRM-A-8-1 | PRM-A-30-1 | PRM-A-8-2 | PRM-A-30-2 | PRM-A-30-3 | PRM-A-30-4 | |
| PRM-A | 2.8 ± 1.0 | 7.5 ± 0.7 | 32 ± 25 | 8.0 ± 0.0 | 15 ± 7.1 | 50 | 32.5 ± 24.7 |
| GNA | 0.48 ± 0.28 | 2.5 ± 0.0 | 4.0 ± 0.0 | 0.90 ± 0.14 | 4.85 ± 3.04 | 19.0 ± 15.6 | 13.0 ± 9.9 |
| HHA | 0.29 ± 0.19 | 1.85 ± 0.49 | 5.5 ± 2.1 | 0.55 ± 0.35 | 5.0 ± 1.4 | 16.0 ± 5.7 | 8.0 ± 2.8 |
| DS-5000 | 0.33 ± 0.12 | 0.30 ± 0.14 | 0.8 ± 0.0 | 0.3 ± 0.0 | 0.28 ± 0.17 | 1.25 ± 0.35 | 1.25 ± 0.35 |
| AMD3100 | 0.05 ± 0.03 | 0.019 ± 0.002 | 0.045 ± 0.007 | 0.036 ± 0.006 | 0.070 ± 0.028 | 0.06 | 0.08 |
| MAb 2G12 | 1.1 ± 0.12 | >50 | >50 | >50 | >50 | >50 | >50 |
| MAb B-12 | 0.012 ± 0.011 | 0.020 ± 0.017 | 0.021 ± 0.009 | 0.017 ± 0.005 | |||
| MAb NEA-9205 | 0.0003 ± 0.00007 | 0.0003 ± 0.0002 | 0.025 ± 0.006 | 0.0004 ± 0.0003 | |||
| MAb F105 | 0.17 ± 0.05 | 0.68 ± 0.50 | ≥1 | 0.80 ± 0.56 | |||
a
Data are expressed as the EC50 (μg/ml) for inhibition of HIV-1-induced cytopathic effect in CEM cell cultures.